Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir ABLTS:0GP7 -1.50%48 Market Cap is kr1,112.29 Mil as of Aug. 04, 2026. GuruFocus rates LTS:0GP7 with a GF Score™ of 48/100 and a GF Value™ of kr1.03 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Medivir AB ranks better than 50.39% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Medivir AB's share price for the quarter that ended in Mar. 2026 was kr2.3. Medivir AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 538.67 Mil. Therefore, Medivir AB's market cap for the quarter that ended in Mar. 2026 was kr1,238.94 Mil.
Medivir AB's quarterly market cap
declined
from Sep. 2025 (kr188.90 Mil) to Dec. 2025 (kr181.04 Mil) but then
increased
from Dec. 2025 (kr181.04 Mil) to Mar. 2026 (kr1,238.94 Mil).
Medivir AB's annual market cap
declined
from Dec. 2023 (kr363.09 Mil) to Dec. 2024 (kr271.24 Mil) and
declined
from Dec. 2024 (kr271.24 Mil) to Dec. 2025 (kr181.04 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Medivir AB's Enterprise Value for Today is kr1,001.47 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Medivir AB Market Cap Related Terms
Medivir AB Market Cap Historical Data
* Premium members only.
The historical data trend for Medivir AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GP7 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Medivir AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Medivir AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Medivir AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (LTS:0GP7) has a Market Cap of kr1,112.29 Mil as of Aug. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #706 out of 1423 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Medivir AB's Market Cap too high?
Medivir AB's current Market Cap is kr1,112.29 Mil. Based on the distribution chart, Medivir AB ranks #706 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medivir AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #706 out of 1423 companies for Market Cap. This puts Medivir AB in the upper half of its industry. The industry median Market Cap is 114.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.69, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Market Cap is 114.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Market Cap is kr1,112.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.03, compared to a current price of kr1.78 — trading 72.7% above its estimated fair value. The current Market Cap is kr1,112.29 Mil. Medivir AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Market Cap is kr1,112.29 Mil as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.78 is trading 72.7% above its estimated GF Value™ of kr1.03.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
Market Cap: kr1,112.29 Mil
GF Value™: kr1.03 vs. price of kr1.78 (72.7% above fair value)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
48GF Score
Get the complete analysis for LTS:0GP7
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
